Alfonzo-Méndez MA, et al. (2018) Different phosphorylation patterns regulate α-adrenoceptor signaling and desensitization. Biochim Biophys Acta 1865, 842-854 29551601

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S300-p - ADRA1D (human) ▲

Modsite: KRERGKAsEVVLRIH SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S300‑p, ADRA1D (mouse): S294‑p, ADRA1D (rat): S294‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCA (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE GRK2 (human) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase paroxetine decrease phorbol_ester increase Go_6976 decrease Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S323-p - ADRA1D (human) ▲

Modsite: DGAHGMRsAKGHtFR SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S323‑p, ADRA1D (mouse): S317‑p, ADRA1D (rat): S317‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GRK2 (human) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme KINASE PKCA (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase paroxetine decrease phorbol_ester increase Go_6976 decrease Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

T328-p - ADRA1D (human) ▲

Modsite: MRsAKGHtFRssLsV SwissProt Entrez-Gene Orthologous residues ADRA1D (human): T328‑p, ADRA1D (mouse): T322‑p, ADRA1D (rat): T322‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S331-p - ADRA1D (human) ▲

Modsite: AKGHtFRssLsVRLL SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S331‑p, ADRA1D (mouse): S325‑p, ADRA1D (rat): S325‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes norepinephrine increase Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S332-p - ADRA1D (human) ▲

Modsite: KGHtFRssLsVRLLK SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S332‑p, ADRA1D (mouse): S326‑p, ADRA1D (rat): S326‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCA (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE GRK2 (human) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase paroxetine decrease phorbol_ester increase Go_6976 decrease Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S334-p - ADRA1D (human) ▲

Modsite: HtFRssLsVRLLKFS SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S334‑p, ADRA1D (mouse): S328‑p, ADRA1D (rat): S328‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCA (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE GRK2 (human) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase paroxetine decrease phorbol_ester increase Go_6976 decrease Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

T442-p - ADRA1D (human) ▲

Modsite: GHHWRAStSGLRQDC SwissProt Entrez-Gene Orthologous residues ADRA1D (human): T442‑p, ADRA1D (mouse): L430‑p, ADRA1D (rat): T434‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

T507-p - ADRA1D (human) ▲

Modsite: LGPFRRPtTQLRAKV SwissProt Entrez-Gene Orthologous residues ADRA1D (human): T507‑p, ADRA1D (mouse): T497‑p, ADRA1D (rat): T497‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S515-p - ADRA1D (human) ▲

Modsite: TQLRAKVssLsHKIR SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S515‑p, ADRA1D (mouse): S505‑p, ADRA1D (rat): S505‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S516-p - ADRA1D (human) ▲

Modsite: QLRAKVssLsHKIRA SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S516‑p, ADRA1D (mouse): S506‑p, ADRA1D (rat): S506‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GRK2 (human) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme KINASE PKCA (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase paroxetine decrease phorbol_ester increase Go_6976 decrease Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization

S518-p - ADRA1D (human) ▲

Modsite: RAKVssLsHKIRAGG SwissProt Entrez-Gene Orthologous residues ADRA1D (human): S518‑p, ADRA1D (mouse): S508‑p, ADRA1D (rat): S508‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site Relevant cell lines - cell types - tissues:  Flp-In T-Rex-293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCA (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE GRK2 (human) transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase norepinephrine increase paroxetine decrease phorbol_ester increase Go_6976 decrease Downstream Regulation Effect of modification (function):  receptor internalization, altered Effect of modification (process):  signaling pathway regulation Comments:  regulates ERK signaling pathway, induces calcium signaling de-sensitization